Hemostemix Inc (PK) (HMTXF) Börsenkurse

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) fro... Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced from the patient's blood. The Company is selling exempt compassionate treatments to individuals afflicted with critical limb ischemia, for example, and conducting clinical trials to commercialize its lead product, ACP-01, for the treatment of critical limb ischemia and peripheral arterial disease, and heart disease (ischemic cardiomyopathy, dilated cardiomyopathy). Mehr anzeigen